EORTC


Also found in: Acronyms, Wikipedia.

EORTC

Abbreviation for:
European Organisation for the Research and Treatment of Cancer
References in periodicals archive ?
En este sentido, sigue un camino similar al del cuestionario de la EORTC.
Andrew Gengos, ImmunoCellular's Chief Executive Officer said, "Working with the EORTC is a key step in our strategy to establish a network of relationships within the clinical oncology community to support the conduct of the ICT-107 Phase 3 trial.
Another paper in the issue describes the YOU infrastructure: one of the four infrastructures that EORTC invested in to optimize and streamline modern clinical research.
Both multinational and multidisciplinary, the EORTC Network comprises more than 4000 collaborators from all disciplines involved in cancer treatment and research in more than 800 hospitals and institutions in over 35 countries.
The EORTC QLQ-C30 includes Global Health Status\QoL, Functional scales and Symptom scale/ items.
Aspectos de la comunicacion se han evaluado en diferentes cuestionarios de Calidad de Vida de la EORTC.
Although common sense favours preservation of kidney function especially with smaller tumours where a significant number are either benign or have less aggressive behaviour, the obsession in achieving ever-higher rates of PN with highly complex tumours in patients with normal renal function may have waned following the publication of the EORTC trial.
The EORTC promotes multidisciplinary cancer research in Europe and is linked to other leading biomedical research organizations around the world.
The EORTC QoL Questionnaires like QLQ-C30, known as core questionnaire and QLQ-BR23, known as breast cancer module were administered to the patients on initial chemotherapeutic cycles ([less than or equal to] 2 cycles) and the scores were recorded as Review-I, followed by Review-II on final chemotherapeutic cycles while they were undergoing [greater than or equal to] 5 cycle treatment.
A 12 country field study of the EORTC QLQ-C30 (version 3.
This conversion to full approval was based on the totality of evidence of Avastin in glioblastoma, including data from the Phase III EORTC 26101 study.
The cooperative group sponsored clinical trial will evaluate DKN-01 in combination with atezolizumab (TECENTRIQ) +/- paclitaxel in advanced esophagogastric malignancies and DKN-01 + atezolizumab in advanced biliary tract cancers at EORTC centers across Europe.